The European Medicines Agency (EMA) announced on Wednesday 3 November that it had terminated the rolling review of the Covid-19 treatment candidate from the US pharmaceutical company Eli Lilly.
Identified by the European Commission as one of the most promising therapeutic solutions for SARS-CoV-2 (see EUROPE B12819A21), this potential treatment, combining the antibodies bamlanivimab and etesevimab, had been the subject of a European advance purchase agreement for up to 220,000 doses. At the...